Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin

Pharmacotherapy

Volumn 31, Issue 10, 2011, Pages 942-950

  Shin, Jaekyu ^a   Pauly, Daniel F ^b   Pacanowski, Michael A ^a   Langaee, Taimour ^a   Frye, Reginald F ^a   Johnson, Julie A ^a,b  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Atorvastatin; Clarithromycin; CYP; CYP3A5 genotype; Cytochrome P450; Drug interaction; Pharmacogenetics

Indexed keywords

ATORVASTATIN; CLARITHROMYCIN; CYSTEINE; CYTOCHROME P450 3A5; THREONINE;

ADULT; ALLELE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; FEMALE; GENETIC POLYMORPHISM; GENETIC SCREENING; GENOTYPE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; PHARMACOGENETICS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; ALLELES; CLARITHROMYCIN; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; FEMALE; GENOTYPE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PROSPECTIVE STUDIES; PYRROLES; YOUNG ADULT;

EID: 80053339932     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.31.10.942     Document Type: Article

References (30)

1. Pfizer Inc. Lipitor (atorvastatin) package insert. New York, NY; 2009.
2. Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 2009;86:197-203.
3. Backman JT, Luurila H, Neuvonen M, Neuvonen PJ. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin Pharmacol Ther 2005;78:154-67. (Pubitemid 41112284)
4. Hermann M, Bogsrud MP, Molden E, et al. Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy. Clin Pharmacol Ther 2006;79:532-9. (Pubitemid 43833450)
5. Skottheim IB, Gedde-Dahl A, Hejazifar S, Hoel K, Asberg A. Statin-induced myotoxicity: the lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro. Eur J Pharm Sci 2008;33:317-25.
6. Jacobsen W, Kuhn B, Soldner A, et al. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos 2000;28:1369-78.
7. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681-90. (Pubitemid 37430274)
8. Sipe BE, Jones RJ, Bokhart GH. Rhabdomyolysis causing AV blockade due to possible atorvastatin, esomeprazole, and clarithromycin interaction. Ann Pharmacother 2003;37:808-11. (Pubitemid 36618365)
9. U.S. Food and Drug Administration. Drug development and drug interactions: table of substrates, inhibitors and inducers. Available from www.fda.gov/Drugs/DevelopmentApproval Process/DevelopmentResources/ DrugInteractionsLabeling/ucm081177.htm. Accessed April 1, 2011.
10. Koch I, Weil R, Wolbold R, et al. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos 2002;30:1108-14.
11. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27:383-91. (Pubitemid 32268418)
12. Lee SJ, Usmani KA, Chanas B, et al. Genetic findings and functional studies of human CYP3A5 single-nucleotide polymorphisms in different ethnic groups. Pharmacogenetics 2003;13:461-72.
13. Solus JF, Arietta BJ, Harris JR, et al. Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics 2004;5:895-931. (Pubitemid 39386756)
14. Hustert E, Haberl M, Burk O, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001;11:773-9.
15. Huang W, Lin YS, McConn DJ II, et al. Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metab Dispos 2004;32:1434-45. (Pubitemid 39564564)
16. Niwa T, Murayama N, Emoto C, Yamazaki H. Comparison of kinetic parameters for drug oxidation rates and substrate inhibition potential mediated by cytochrome P450 3A4 and 3A5. Curr Drug Metab 2008;9:20-33. (Pubitemid 351201667)
17. Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 2007;82:726-33.
18. He YJ, Zhang W, Chen Y, et al. Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta 2009;405:49-52.
19. Lee YJ, Lee MG, Lim LA, Jang SB, Chung JY. Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects. Int J Clin Pharmacol Ther 2010;48:36-45.
20. Langaee TY, Gong Y, Yarandi HN, et al. Association of CYP3A5 polymorphisms with hypertension and antihypertensive response to verapamil. Clin Pharmacol Ther 2007;81:386-91.
21. Jemal M, Ouyang Z, Chen BC, Teitz D. Quantitation of the acid and lactone forms of atorvastatin and its biotransformation products in human serum by high-performance liquid chromatography with electrospray tandem mass spectrometry. Rapid Commun Mass Spectrom 1999;13:1003-15. (Pubitemid 29257202)
22. Shin J, Pauly DF, Johnson JA, Frye RF. Simplified method for determination of clarithromycin in human plasma using protein precipitation in a 96-well format and liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2008;871:130-4.
23. Kantola T, Kivisto KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharm Ther 1998;64:58-65. (Pubitemid 28377331)
24. Norris N. The standard errors of the geometric and harmonic means and their application to index numbers. Ann Mathematic Stat 1940;11:445-8.
25. Park JE, Kim KB, Bae SK, Moon BS, Liu KH, Shin JG. Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin. Xenobiotica 2008;38:1240-51.
26. Kivisto KT, Niemi M, Schaeffeler E, et al. Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics 2004;14:523-5.
27. Wilke RA, Moore JH, Burmester JK. Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage. Pharmacogenet Genomics 2005;15:415-21.
28. Willrich MA, Hirata MH, Genvigir FD, et al. CYP3A53A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia. Clin Chim Acta 2008;398:15-20.
29. Pinto AG, Wang YH, Chalasani N, et al. Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression. Clin Pharmacol Ther 2005;77:178-88. (Pubitemid 40269133)
30. Keskitalo JE, Kurkinen KJ, Neuvoneni PJ, Niemi M. ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. Clin Pharmacol Ther 2008;84:457-61.